Maxcyte
Maxcyte:
global cell therapy company providing proprietary non-viral cell engineering technology for the next generation of cell-based therapies including gene editing and immuno-oncology. MaxCyte has a blue chip client base, 120+ issued licences, and potential $800m+ pre-commercial milestone potential from existing licenses. In addition, MaxCyte is seeking independent financing for CARMA (mRNA-based CAR platform) to establish it as a separate therapeutics company and allow MaxCyte to focus on its core cell-engineering business.
Sector/Industry:
Healthcare/Medical Diagnostics & Research
Characteristics:
Based in...
US - South Atlantic
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Oncology
Listing
Europe, Public
Market Cap
<100MM
Therapeutic Modalities
Cell Therapy, Gene editing, Gene Therapy
Website:
Address:
22 Firstfield Road
Suite 110
Gaithersburg, MD 20878
United States
Suite 110
Gaithersburg, MD 20878
United States
More info:
My account:
Company Participants at Solebury Trout Virtual Global Healthcare Conference Series
- Douglas Doerfler, President & CEO
Top 10 Holders of MaxCyte, Inc.
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| Casdin Capital LLC | 21.97 | 11,281,334 | 0.00 | Stakes | 10/30/20 |
| River & Mercantile Asset Management LLP | 13.34 | 6,849,975 | 0.00 | Stakes | 10/30/20 |
| Canaccord Genuity Wealth Ltd. | 6.38 | 3,275,350 | 0.00 | Stakes | 10/30/20 |
| Unicorn Asset Management Ltd. | 5.88 | 3,017,857 | 0.00 | Stakes | 10/30/20 |
| BlackRock Investment Management (UK) Ltd. | 4.15 | 2,799,279 | 0.00 | Stakes | 1/21/20 |
| Legal & General Investment Management Ltd. | 3.80 | 2,562,752 | 0.00 | Stakes | 1/21/20 |
| Chelverton Asset Management Ltd. | 3.56 | 2,400,000 | 0.00 | Funds | 6/30/20 |
| Artisan Partners LP | 3.22 | 1,652,546 | 0.00 | Funds | 9/30/20 |
| Amati Global Investors Ltd. | 2.65 | 1,359,728 | 0.00 | Funds | 12/31/20 |
| Amati Global Investors Ltd. (Venture Capital) | 1.92 | 986,693 | 0.00 | Funds | 7/31/20 |
Top 10 Holders of MaxCyte, Inc. Reg S
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| Amati Global Investors Ltd. | 12.37 | 1,225,000 | 0.00 | Funds | 12/31/20 |
| River & Mercantile Asset Management LLP | 4.38 | 433,500 | 0.00 | Funds | 12/31/20 |
Top 10 Holders of MaxCyte, Inc. TEMP
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| BlackRock Investment Management (UK) Ltd. | 3.68 | 219,041 | 0.00 | Stakes | 1/21/20 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.